Title: Use of a Galectin-1-Targeted RNAi-Based Approach for the Treatment of Cancer
Patent Number: 7,964,575
Filed: March 9, 2006
Lead Inventor: Isabelle Camby, Universite Libre de Bruxelles
The invention relates to an “RNAi molecule suitable for reducing the expression of galectin-1,” the patent's abstract states. It also relates to the use of the molecule as a “medicament, or for the manufacture of a medicament for treating and/or for delaying the progression of cancer, preferably glioma, pancreatic cancer, head and neck cancer, melanoma, non-small cell lung cancer, and non-Hodgkin's lymphoma.
“The ... invention also relates to compositions and methods for treating and for delaying the progression of cancer ... for reducing the migration of tumor cells … and/or for enhancing the efficacy of cancer therapies for the treatment of cancer,” the abstract adds.
Title: Conjugates and Compositions for Cellular Delivery
Patent Number: 7,964,578
Filed: Oct. 16, 2008
Lead Inventor: Chandra Vargeese, Sirna Therapeutics (Merck)
“This invention features conjugates, degradable linkers, compositions, methods of synthesis, and applications thereof, including cholesterol, folate, galactose, galactosamine, N-acetyl galactosamine, PEG, phospholipid, peptide, and human serum albumin-derived conjugates of biologically active compounds, including ... dsRNA, siNA, siRNA, [and] triplex oligonucleotides,” the patent's abstract states.
Title: Gene Expression-Suppression Agents
Patent Number: 7,964,714
Filed: May 12, 2003
Lead Inventor: Yangxian Xiao, Potomac Pharmaceuticals
The invention, the patent's abstract states, comprises “a method is … for making gene suppression agents to be used in eukaryotic cells by using a recombinant DNA construct containing at least one transcriptional unit compromising a transcriptional promoter, a template sequence for making a RNA molecule, and a transcriptional terminator. Mechanisms of the RNA mediated gene suppression include, but are not limited to, RNA interference. The use of the agents as tools for biomedical research as well as medicinal products is also disclosed.”
Title: RNAi Probes Targeting Cancer-Related Proteins
Patent Number: 7,964,717
Filed: Feb. 23, 2006
Lead Inventor: Martin Gleave, University of British Columbia
The patent, its abstract states, claims “RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma, and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf.
“The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types ... and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment,” the abstract adds.
Title: Use of microRNA as a Biomarker of Immunomodulatory Drug Activity
Patent Number: 7,964,354
Filed: Dec. 19, 2008
Lead Inventor: Gregory Ferguson, Celegene
The invention comprises “methods of determining the activity of an immunomodulatory compound by measuring the presence of an miRNA in a sample,” the patent's abstract states. “Additionally disclosed are methods of assessing the patient compliance in patients treated with an immunomodulatory compound.”
Title: RNAi-Mediated Inhibition of Tumor Necrosis Factor-Alpha-Related Conditions
Application Number: 20110142767
Filed: Feb. 25, 2011
Lead Inventor: John Yanni, Alcon
The patent application, its abstract states, claims “RNA interference ... for inhibition of tumor necrosis factor-alpha by silencing TNF-alpha cell-surface receptor TNF receptor-1 mRNA expression, or by silencing TNF-alpha-converting enzyme mRNA expression. Silencing such TNF-alpha targets, in particular, is useful for treating patients having a TNF-alpha-related condition or at risk of developing a TNF-alpha-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.”
Title: Compositions and Methods for Inhibition of VEGF
Application Number: 20110142915
Filed: Dec. 6, 2010
Inventor: Nadine Dejneka, Opko Ophthalmics (Opko Health)
The invention, the patent application's abstract states, comprises “siRNA compositions and methods useful for inhibiting expression of vascular endothelial growth factor isoforms. Diseases which involve angiogenesis stimulated by over-expression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering small interfering RNAs as disclosed.”
Title: Novel RNAi Therapeutics for Treatment of Hepatitis C Infection
Application Number: 20110142921
Filed: Feb. 25, 2011
Inventor: Hengli Tang, Florida State University
The invention, the patent application's abstract states, comprises “small interfering RNAs or small hairpin RNA, and compositions comprising same ... that specifically target human cyclophilin A to effectively inhibit hepatitis C infection in a cell. Such siRNA and shRNAs may have a length of from about 19 to about 29 contiguous nucleotides corresponding to a specific region of human cyclophilin A cDNA of from about nucleotide 155 to about nucleotide 183 having particular potency against CyPA and HCV.
“Such siRNA and shRNAs may be formulated as naked compositions or as pharmaceutical compositions,” the abstract adds. “DNA polynucleotides, plasmids, and viral or non-viral vectors are also provided that encode siRNA or shRNA molecules, which may be delivered directly to cells or in combination with known delivery agents, such as lipids, polymers, [or] encapsulated lipid particles, such as liposomes. Methods for treating, managing inhibiting, preventing, etc., HCV infection using such siRNA and shRNAs and compositions comprising same are also provided.”
Title: siRNA and Methods of Manufacture
Application Number: 20110143400
Filed: Dec. 15, 2010
Lead Inventor: Samuel Reich, Opko Ophthalmics (Opko Health)
The invention, the patent application's abstract states, comprises “double-stranded RNA of about 19 to about 25 nucleotides in length capable of regulating gene expression by RNA interference. ... Such double-stranded RNA are particularly useful for treating disease or conditions associated with a target mRNA or gene. Methods of manufacture and methods of use of the double-stranded RNA are also provided.”